Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication
Launched by DANA-FARBER CANCER INSTITUTE ·
Trial Information
Current as of September 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help doctors and patients with serious illnesses, like advanced cancer, have important conversations about care goals. The study will test how well computer programs, called Large Language Models (a type of artificial intelligence), can create clear summaries of these conversations. Researchers also want to see if it’s practical to share these summaries with patients and doctors and to hear what both groups think about them.
People aged 65 to 74 who have cancer may be able to join this study. If you participate, you might receive summaries generated by the AI that explain the discussions about your care. The study will help doctors understand if these summaries are accurate and useful in supporting communication about serious illness and end-of-life care. This trial is not yet recruiting participants but aims to improve how care conversations are documented and shared.
Gender
ALL
Eligibility criteria
About Dana Farber Cancer Institute
The Dana-Farber Cancer Institute is a premier cancer research and treatment institution located in Boston, Massachusetts. Renowned for its commitment to advancing cancer care through innovative research, the institute integrates cutting-edge clinical trials with a multidisciplinary approach to patient care. With a focus on translating scientific discoveries into effective therapies, Dana-Farber collaborates with a network of leading researchers and healthcare professionals to improve outcomes for patients with cancer. The institute’s dedication to education, advocacy, and community engagement further underscores its mission to eradicate cancer and enhance the quality of life for those affected by the disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Christopher Manz, MD
Principal Investigator
Dana-Farber Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported